PD-L1, TMB, and other potential predictors of response to immunotherapy for hepatocellular carcinoma: how can they assist drug clinical trials?
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PD-L1, TMB, and other potential predictors of response to immunotherapy for hepatocellular carcinoma: how can they assist drug clinical trials?
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume -, Issue -, Pages 1-9
Publisher
Informa UK Limited
Online
2021-08-25
DOI
10.1080/13543784.2021.1972969
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC).
- (2021) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer
- (2021) Alessandro Rizzo et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Immune-based combinations for advanced hepatocellular carcinoma: shaping the direction of first-line therapy
- (2021) Alessandro Rizzo et al. Future Oncology
- DNA damage response alterations in gastric cancer: knocking down a new wall
- (2021) Angela Dalia Ricci et al. Future Oncology
- Identification of immune-related lncRNA signature for predicting immune checkpoint blockade and prognosis in hepatocellular carcinoma
- (2021) Qianhui Xu et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy
- (2021) Rangarirai Makuku et al. Journal of Immunology Research
- PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer
- (2021) Alessandro Rizzo et al. Cancers
- A review on the role of gut microbiota in immune checkpoint blockade therapy for cancer
- (2021) Esther Kim et al. MAMMALIAN GENOME
- NASH limits anti-tumour surveillance in immunotherapy-treated HCC
- (2021) Dominik Pfister et al. NATURE
- Advances in immunotherapy for hepatocellular carcinoma
- (2021) Bruno Sangro et al. Nature Reviews Gastroenterology & Hepatology
- Combination Immunotherapy for Hepatocellular Carcinoma: Where Are We Currently?
- (2021) Pedro Luiz Serrano Uson Junior et al. SEMINARS IN LIVER DISEASE
- The Association Between Inflammation and Immunosuppression: Implications for ICI Biomarker Development
- (2021) Danielle Benedict Sacdalan et al. OncoTargets and Therapy
- Gut Microbiota and Antitumor Immunity: Potential Mechanisms for Clinical Effect
- (2021) Erez N. Baruch et al. Cancer Immunology Research
- Lessons From Immune Checkpoint Inhibitor Trials in Hepatocellular Carcinoma
- (2021) Raphael Mohr et al. Frontiers in Immunology
- Combination therapy for advanced hepatocellular carcinoma: do we see the light at the end of the tunnel?
- (2021) Ti Zhang et al. Hepatobiliary Surgery and Nutrition
- Hepatocellular Carcinoma: An Overview of the Changing Landscape of Treatment Options
- (2021) Andreas Koulouris et al. Journal of Hepatocellular Carcinoma
- Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma?
- (2021) Alessandro Rizzo et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Atezolizumab in advanced hepatocellular carcinoma: good things come to those who wait
- (2021) Alessandro Rizzo et al. Immunotherapy
- WSX1 act as a tumor suppressor in hepatocellular carcinoma by downregulating neoplastic PD-L1 expression
- (2021) Man Wu et al. Nature Communications
- Evolving Treatment of Advanced Hepatocellular Carcinoma in the Asia–Pacific Region: A Review and Multidisciplinary Expert Opinion
- (2021) Sadahisa Ogasawara et al. Cancers
- Biomarkers in Hepatobiliary Cancers: What Is Useful in Clinical Practice?
- (2021) Alice Boilève et al. Cancers
- Gut Microbiome Modulates Response to Cancer Immunotherapy
- (2020) Md Abdul Wadud Khan et al. DIGESTIVE DISEASES AND SCIENCES
- The progress and confusion of anti-PD1/PD-L1 immunotherapy for patients with advanced non-small cell lung cancer
- (2020) Shuling Zhang et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Molecular therapies for HCC: Looking outside the box
- (2020) Sandrine Faivre et al. JOURNAL OF HEPATOLOGY
- Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma
- (2020) Ann-Lii Cheng et al. JOURNAL OF HEPATOLOGY
- Gut microbiome in HCC – Mechanisms, diagnosis and therapy
- (2020) Robert F. Schwabe et al. JOURNAL OF HEPATOLOGY
- Immune‐related long noncoding RNA signature for predicting survival and immune checkpoint blockade in hepatocellular carcinoma
- (2020) Yaqiong Zhang et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Atezolizumab plus Bevacizumab — A Landmark in Liver Cancer
- (2020) Robin K. Kelley NEW ENGLAND JOURNAL OF MEDICINE
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune-based therapies for hepatocellular carcinoma
- (2020) David J. Pinato et al. ONCOGENE
- Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project
- (2020) Diana M Merino et al. Journal for ImmunoTherapy of Cancer
- Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma
- (2020) Masatoshi Kudo Cancers
- Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial
- (2020) L. Paz-Ares et al. ANNALS OF ONCOLOGY
- Associations among the mutational landscape, immune microenvironment, and prognosis in Chinese patients with hepatocellular carcinoma
- (2020) Zhi-Qiang Hu et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Genomic Database Analysis of Uterine Leiomyosarcoma Mutational Profile
- (2020) Annalisa Astolfi et al. Cancers
- Immuno-Oncotherapeutic Approaches in Advanced Hepatocellular Carcinoma
- (2020) Robin Park et al. Vaccines
- Unique TP53 neoantigen and the immune microenvironment in long-term survivors of Hepatocellular carcinoma
- (2020) Huayu Yang et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Qualification of tumour mutational burden by targeted next‐generation sequencing as a biomarker in hepatocellular carcinoma
- (2020) Ching Ngar Wong et al. LIVER INTERNATIONAL
- Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma
- (2020) Johann von Felden et al. ONCOGENE
- The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma
- (2020) Matthias Pinter et al. JAMA Oncology
- Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma
- (2020) Mohamed A. Abd El Aziz et al. Vaccines
- The DNA damage repair (DDR) pathway in biliary tract cancer (BTC): a new Pandora’s box?
- (2020) Angela Dalia Ricci et al. ESMO Open
- Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater
- (2019) Martin Reck et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor mutational load predicts survival after immunotherapy across multiple cancer types
- (2019) Robert M. Samstein et al. NATURE GENETICS
- Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma
- (2019) Junyu Long et al. EBioMedicine
- Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non‐Small Cell Lung Cancer
- (2019) Young Kwang Chae et al. ONCOLOGIST
- MSI/MMR-deficient tumor diagnosis: Which standard for screening and for diagnosis? Diagnostic modalities for the colon and other sites: Differences between tumors
- (2019) Magali Svrcek et al. BULLETIN DU CANCER
- Hepatocellular Carcinoma
- (2019) Augusto Villanueva NEW ENGLAND JOURNAL OF MEDICINE
- Exploring the emerging role of the microbiome in cancer immunotherapy
- (2019) Jessica Fessler et al. Journal for ImmunoTherapy of Cancer
- Building on the anti-PD1/PD-L1 Backbone: Combination Immunotherapy for Cancer
- (2019) Alvaro H Ingles Garces et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Combination of CTLA-4 and PD-1 blockers for treatment of cancer
- (2019) Anand Rotte JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma
- (2019) Marina Ruiz de Galarreta et al. Cancer Discovery
- Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma
- (2019) Yi Zheng et al. Journal for ImmunoTherapy of Cancer
- Combination of TMB and CNA stratifies prognostic and predictive responses to immunotherapy across metastatic cancer
- (2019) Li Liu et al. CLINICAL CANCER RESEARCH
- MIR155HG is a prognostic biomarker and associated with immune infiltration and immune checkpoint molecules expression in multiple cancers
- (2019) Lirong Peng et al. Cancer Medicine
- LBA38_PRCheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)
- (2019) T Yau et al. ANNALS OF ONCOLOGY
- Hepatocellular carcinoma: an update on investigational drugs in phase I and II clinical trials
- (2019) Anne Noonan et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges
- (2019) Zuzana Macek Jilkova et al. Cancers
- Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer
- (2018) Martin Reck Immunotherapy
- Hepatocellular carcinoma
- (2018) Alejandro Forner et al. LANCET
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
- (2018) Andrew X Zhu et al. LANCET ONCOLOGY
- The emerging clinical relevance of genomics in cancer medicine
- (2018) Michael F. Berger et al. Nature Reviews Clinical Oncology
- DNA mismatch repair in cancer
- (2018) Marina Baretti et al. PHARMACOLOGY & THERAPEUTICS
- The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients
- (2018) Vyara Matson et al. SCIENCE
- Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: a proof of concept
- (2018) Stefania De Lorenzo et al. Scientific Reports
- Cancer immunotherapy: broadening the scope of targetable tumours
- (2018) Jitske van den Bulk et al. Open Biology
- Monitoring Immune Checkpoint Regulators as Predictive Biomarkers in Hepatocellular Carcinoma
- (2018) Ritu Shrestha et al. Frontiers in Oncology
- Molecular therapies and precision medicine for hepatocellular carcinoma
- (2018) Josep M. Llovet et al. Nature Reviews Clinical Oncology
- Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
- (2018) T A Chan et al. ANNALS OF ONCOLOGY
- Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next Generation Sequencing for Matching Patients to Targeted and Immune Therapies
- (2018) James J Harding et al. CLINICAL CANCER RESEARCH
- Nivolumab for the treatment of hepatocellular carcinoma
- (2018) Fabian Finkelmeier et al. Expert Review of Anticancer Therapy
- Microbiota and cancer immunotherapy: in search of microbial signals
- (2018) Raad Z Gharaibeh et al. GUT
- State-of-the-art strategies for targeting the DNA damage response in cancer
- (2018) Patrick G. Pilié et al. Nature Reviews Clinical Oncology
- Directing the use of DDR kinase inhibitors in cancer treatment
- (2017) Inger Brandsma et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features
- (2017) Daniela Sia et al. GASTROENTEROLOGY
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- The gut microbiome and liver cancer: mechanisms and clinical translation
- (2017) Le-Xing Yu et al. Nature Reviews Gastroenterology & Hepatology
- Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
- (2017) V. Gopalakrishnan et al. SCIENCE
- Microsatellite Instability
- (2017) Liisa Chang et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
- (2017) Hashem O. Alsaab et al. Frontiers in Pharmacology
- Advancements in Next-Generation Sequencing
- (2016) Shawn E. Levy et al. Annual Review of Genomics and Human Genetics
- Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features
- (2016) Julien Calderaro et al. HEPATOLOGY
- Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma
- (2016) Tai Hato et al. Immunotherapy
- Classification and characterization of microsatellite instability across 18 cancer types
- (2016) Ronald J Hause et al. NATURE MEDICINE
- Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients
- (2016) Marius Ilie et al. VIRCHOWS ARCHIV
- Novel drugs in clinical development for hepatocellular carcinoma
- (2015) Oliver Waidmann et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Genetic Landscape and Biomarkers of Hepatocellular Carcinoma
- (2015) Jessica Zucman-Rossi et al. GASTROENTEROLOGY
- Targeting the DNA Damage Response in Cancer
- (2015) Mark J. O’Connor MOLECULAR CELL
- The cancer genome
- (2009) Michael R. Stratton et al. NATURE
- Microsatellite instability in hepatocellular carcinoma in non-cirrhotic liver in patients older than 60 years
- (2008) Roberto Togni et al. HEPATOLOGY RESEARCH
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now